RNA viruses as virotherapy agents

Cancer Gene Therapy

Volumn 9, Issue 12, 2002, Pages 961-966

  Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED RNA; INTERFERON; ONCOLYTIC VIRUS; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELLULAR IMMUNITY; DRUG SPECIFICITY; ENZYME ACTIVATION; GENE THERAPY; INFLUENZA VIRUS; INTERFERON PRODUCTION; MEASLES VIRUS; MUMPS VIRUS; NEWCASTLE DISEASE PARAMYXOVIRUS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REOVIRUS; REVIEW; RNA VIRUS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIROTHERAPY; VIRUS CULTURE; ANIMAL; GENE VECTOR; GENETICS; HUMAN; METHODOLOGY; NEOPLASM; VIROLOGY;

INFLUENZA VIRUS; MEASLES VIRUS; MUMPS VIRUS; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE; POLIOVIRUS; REOVIRUS SP.; RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; RNA VIRUSES;

EID: 0036905014     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700535     Document Type: Review

References (48)

1. Russell SJ. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer. 1994;8:1165-1171.
2. Russell SJ. Replicating vectors for cancer therapy: A question of strategy. Semin Cancer Biol. 1994;5:437-443.
3. Asada T. Treatment of human cancer with mumps virus. Cancer. 1974;34:1907-1928.
4. Lamb R, Kolakofsky D. Paramyxoviridae: The viruses and their replication. In: Knipe D, Howley P, eds. Fields' Virology. Philadelphia: Lippincott, Williams and Wilkins; 2001:1305-1340.
5. Shimizu Y, Hasumi K, Okudaira Y, et al. Immunotherapy of advanced gynecologic cancer: Patients utilizing mumps virus. Cancer Detect Prev. 1988;12:487-495.
6. Beard CW, Hanson RP. Newcastle disease. In: Hofstad MS, ed. Disease of Poultry. 8th Ed. Ames: Iowa State University Press; 1984:452-470.
7. Reichard KW, Lorence RM, Cascino CJ, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res. 1992;52:448-453.
8. Phuangsab A, Lorence RM, Reichard KW, et al. Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett. 2001;172:27-36.
9. Lorence RM, Katubig BB, Reichard KW, et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 1994;54:6017-6021.
10. Lorence RM, Reichard KW, Katubig BB, et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst. 1994;86:1228-1233.
11. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol. 1999;9:83-99.
12. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20:2251-2266.
13. Griffin D. Measles virus. In: Knipe DM, Howley PM, eds. Fields' Virology, 4th Edition. Philadelphia: Lippincott, Williams and Wilkins; 2001;Vol. 1:1401-1441.
14. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet. 1971:105-106.
15. Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood. 2001;97:3746-3754.
16. Peng K-W, TenEyck C, Galanis E, et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002;62:4656-4662.
17. Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001;98:2002-2007.
18. Peng KW, Facteau S, Wegman T, et al. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med. 2002;8:527-531.
19. Ono N, Tatsuo H, Hidaka Y, et al. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol. 2001;75:4399-4401.
20. Jurianz K, Ziegler S, Garcia-Schuler H, et al. Complement resistance of tumor cells: Basal and induced mechanisms. Mol Immunol. 1999;36:929-939.
21. Erlenhofer C, Duprex WP, Rima BK, et al. Analysis of receptor (CD46, CD150) usage by measles virus. J Gen Virol. 2002;83:1431-1436.
22. Esolen LM, Park SW, Hardwick JM, et al. Apoptosis as a cause of death in measles virus-infected cells. J Virol. 1995;69:3955-3958.
23. Radecke F, Spielhofer P, Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J. 1995;14:5773-5784.
24. Hammond AL, Plemper RK, Zhang J, et al. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol. 2001;75:2087-2096.
25. Peng K, Donovan K, Schneider U, et al. Oncolytic Measles Viruses Displaying a Single Chain Antibody Against CD38, a Myeloma Cell Marker. submitted for publication.
26. Schneider U, Bullough F, Vongpunsawad S, et al. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol. 2000;74:9928-9936.
27. Rose JK, Whitt MA. Rhabdoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields' Virology, 4th Edition. Philadelphia: Lippincott, Williams and Wilkins; 2001;Vol. 1:1221-1244.
28. Belkowski LS, Sen GC. Inhibition of vesicular stomatitis viral mRNA synthesis by interferons. J Virol. 1987;61:653-660.
29. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor- specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821-825.
30. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol. 2001;75:3474-3479.
31. Stojdl DF, Abraham N, Knowles S, et al. The murine double- stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol. 2000;74:9580- 9585.
32. DePolo NJ, Reed JD, Sheridan PL, et al. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther. 2000;2:218-222.
33. Fernandez M, Porosnicu M, Markovic D, et al. Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J Virol. 2002;76:895-904.
34. Tyler KL, Fields BN. Mammalian reoviruses. In: Fields BN, Knipe DM, Howley PM, eds. Fields' Virology. Philadelphia: Lippincott-Raven; 1996:1597-1623.
35. Mundschau LJ, Faller DV. Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie. 1994;76:792-800.
36. Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998;17:3351-3362.
37. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282:1332-1334.
38. Hirasawa K, Nishikawa SG, Norman KL, et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 2002;62:1696-1701.
39. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2002;13:641-652.
40. Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst. 2001;93:903-912.
41. Roner MR. Rescue systems for dsRNA viruses of higher organisms. Adv Virus Res. 1999;53:355-367.
42. Dock G. Influence of complicating diseases upon leukaemia. Am J Med Sci. 1904;127:563-592.
43. Bergmann M, Romirer I, Sachet M, et al. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res. 2001;61:8188-8193.
44. Neumann G, Kawaoka Y. Reverse genetics of influenza virus. Virology. 2001;287:243-250.
45. Hatada E, Saito S, Fukuda R. Mutant influenza viruses with a defective NS1 protein cannot block the activation of PKR in infected cells. J Virol. 1999;73:2425-2433.
46. Racaniello VR. Picornaviridae: The viruses and their replication. In: Knipe DM, Howley PM, eds. Fields' Virology, 4th Edition. Philadelphia: Lippincott, Williams and Wilkins; 2001;Vol. 1:685-722.
47. Evans DJ. Reverse genetics of picomaviruses. Adv Virus Res. 1999;53:209-228.
48. Gromeier M, Lachmann S, Rosenfeld MR, et al. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA. 2000;97:6803-6808.